Year: 2026

Dr. Babar Rao highlights clinically meaningful outcomes with majority of lesions potentially avoiding immediate surgery in non-melanoma Skin Cancer PHILADELPHIA, March 30, 2026 (GLOBE NEWSWIRE) — Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today reported independent clinical validation of its Phase 2 SkinJect® dataset from Dr. Babar Rao, principal investigator of the SKNJCT-003 study and a globally recognized dermatology key opinion leader.  Dr. Rao’s independent assessment reinforces the Company’s view that the dataset is clinically meaningful, decision-grade, and supportive of continued development and regulatory engagement. Dr. Rao, speaking...

FLORHAM PARK, N.J., March 30, 2026 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced that the Company will have a poster presentation at the 2026 Annual Meeting of the American Association for Cancer Research (“AACR”), taking place on April 17 through 22, 2026 in San Diego, California. Presentation Details:Title: Plinabulin Boosts Antitumor Efficacy of Topoisomerase Inhibitor-based Antibody-drug Conjugates Without or With Immune Checkpoint Inhibitor Presenter / Authors: Yingjuan June Lu, Xiaoyan He, Weiwei Cheng, Zhengyan Zhang, James Tonra, Lan Huang Presentation Time: April 21, 2026, 2PM to 5PM PT Location: Poster Section 8 at San Diego Convention Center Session...

MONTRÉAL, March 30, 2026 (GLOBE NEWSWIRE) — Bombardier Inc. (“Bombardier”) today announced that it has extended the expiration date of its previously announced consent solicitation (the “Canadian Consent Solicitation”) in respect of its 7.35% Debentures due 2026 (the “Canadian Notes”). The Consent Deadline (as defined in the Consent Solicitation Statement referred to below) for the Canadian Notes has been extended to 5:00 p.m., Eastern time, on April 10, 2026 (the “Extended Consent Deadline”). As previously announced and described in Bombardier’s Consent Solicitation Statement dated March 16, 2026 (as it may be amended or supplemented, the “Consent Solicitation Statement”), if the requisite consents from holders of Canadian Notes are received on or prior to the Extended Consent Deadline and the supplemental indenture implementing...

– Comprehensive submission includes interim Phase 3 FORTIFY data demonstrating BBP-418’s rapid, consistent treatment effect and favorable safety profile, with statistically significant and clinically meaningful improvements in ambulation and pulmonary function – Based on ongoing discussions with the FDA, BridgeBio anticipates approval with a U.S. launch anticipated in late 2026/early 2027 – If approved, BBP-418 has the potential to become the first and only therapy for individuals living with LGMD2I/R9 and may represent the first approved treatment for any form of LGMD PALO ALTO, Calif., March 30, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced the submission of its New...

TORONTO, Ontario and NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) — Bitfarms Ltd. (NASDAQ/TSX: BITF), a North American digital infrastructure and energy company, will participate in a fireside chat at the Jefferies Virtual Power x Data Center Conference. Jefferies Virtual Fireside ChatDate: Tuesday, March 31, 2026Time: 10:15 AM EasternPresenters: CEO, Ben Gagnon and CFO Jonathan Mir Webcast Link About Bitfarms Ltd.Bitfarms is a North American digital infrastructure and energy company that develops and owns data centers and energy infrastructure for high-performance computing workloads, including artificial intelligence. Bitfarms’ 2.1 GW North American energy portfolio is comprised of energized, under development, and pipeline MW, located in established data center clusters, with robust access to power and fiber infrastructure. Bitfarms...

Jena, Germany, March 30, 2026 (GLOBE NEWSWIRE) —  InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that data from the Phase 3 study of vilobelimab in pyoderma gangrenosum (PG) were featured in an oral presentation during the Late-Breaking Research abstract session at the 2026 American Academy of Dermatology (AAD) Annual Meeting being held March 27-31, 2026, in Denver, CO. The data presented included encouraging signals of clinical activity across multiple measures, with higher rates of complete remission, target ulcer closure, and reductions in ulcer volume, as well as a positive safety profile. The presentation, entitled “Vilobelimab Treatment for Ulcerative Pyoderma Gangrenosum: Results from a Multicenter, Randomized, Placebo...

Nanterre, March 30, 2026 Declaration of transactions on treasury shares(period from 23 to 27 March 2026) As part of the share buyback program authorized by the General Meeting of June 5, 2025 and entrusted to CIC, NEURONES made the following purchases between March 23 and 27, 2026 (ISIN code FR0004050250):Day Total daily volume(in number of shares) Weighted average price(unit daily)03/23/2026 46,392 34.13 €03/24/2026 42,993 33.47 €03/25/2026 11,665 34.58 €03/26/2026 7,166 34.26 €03/27/2026 6,805 34.43 €Total 115,021  As of March 27, 2026, excluding the liquidity contract, NEURONES now holds 230,861 of the 24,328,716 shares comprising the company’s capital (i.e., 0.95%). All press releases relating to the share buyback program are published in the “Regulated Information” section (under “Weekly...

Alignment reached on key elements of ATH434 Phase 3 development program MELBOURNE, Australia and SAN FRANCISCO, March 30, 2026 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received positive regulatory feedback following a Type C Meeting with the U.S. Food and Drug Administration (FDA) regarding its planned Phase 3 development program for ATH434 in Multiple System Atrophy (MSA). The Type C Meeting is part of a multidisciplinary strategy to seek alignment with the FDA on readiness to initiate a Phase 3 pivotal trial in MSA. Alterity received written feedback supporting its plans related to the clinical pharmacology and non-clinical development elements...